Caliway Biopharmaceuticals (TWSE:6919) presented preclinical data on its drug candidate CBL-514 at the European Congress on Obesity.
Animal studies showed that combining CBL-514 with semaglutide or tirzepatide significantly reduces body weight.
With semaglutide, weight loss increased by 91.5%. With tirzepatide, weight regain after discontinuation was reduced.
Liver metabolism also improved: hepatic lipid content dropped by 40.4% and cholesterol by 52.7%.
CBL-514 is designed for subcutaneous fat reduction and cellulite treatment. The company plans to start human clinical trials this year.
